For personal use only

Transcription

1 ABN FOR THE YEAR ENDED 30 JUNE

2 Reporting period: Year ended 30 June Previous corresponding period: Year ended 30 June Results for announcement to the market 000 Revenue from continuing operations Down 100% to Nil Profit (loss) from continuing operations after tax attributable to members Down 212 % to (2,707) Net profit (loss) for the period attributable to members Down 212 % to (2,707) Net tangible asset backing per ordinary share () - current period Net tangible asset backing per ordinary share () - previous corresponding period Franked Dividends Amount per security amount per security Dividend - current reporting period nil nil Dividend - previous corresponding period nil nil The Company did not pay a dividend for the year ended 30 June and it will not pay a dividend for the year ended 30 June. Explanation of Results The Consolidated Group recorded a 2,707,451 loss from operations (: Profit 2,478,187) includes nonrecurring charges of approximately 907,000 in relation to the settlement in China and a one-off write back of 157,185 finalising the lease of the surplus premises. Cash Flow continued to be impacted by the legacy of debts and lease of the previous head office, inherited from the previous Board, for which the Group had to meet its obligations. In addition, significant costs were incurred in achieving reinstatement of the company to its ASX listing. The recovery of funds from China was completed in December and the Company is now in a position to capitalise on the acquisition of its hepatitis B drug compound AGX-1009 and the sunk costs in the research and development of the promising ThromboView technology. Explanation of Revenue No revenue was received during the year. The Group s products are still in development and revenue from those products is not expected until the completion of clinical trials and regulatory approval which cannot be guaranteed. Explanation of Profit (Loss) from Ordinary Activities The Consolidated Group recorded a 2,707,451 loss from operations (: Profit 2,478,187) includes nonrecurring charges of approximately 907,000 in relation to the settlement in China and a one-off write back of 157,185 finalising the lease of the surplus premises.

3 Consolidated Statement of Comprehensive Income Revenue from continuing operations - 6,185 Other income 219,960 46,852 Depreciation and amortisation expense (9,852) (16,135) Employee benefit expense (710,918) (683,956) Finance costs (51,991) (105,237) Foreign exchange losses (670,602) (149,619) Occupancy and administrative expenses (1,448,963) (1,064,849) Research & development expenses (139,565) (141,071) Share based payment expense (52,694) (10,517) Write back of surplus lease space accrual 157,185 - Revaluation increment of financial assets - 4,597,065 Profit (Loss) before income tax (2,707,440) 2,478,718 Income tax expense (11) (531) Profit (Loss) for the year (2,707,451) 2,478,187 Other comprehensive income Exchange differences on translating foreign controlled entities (162,295) (28,203) Other comprehensive income for the year, net of tax (162,295) (28,203) Total comprehensive income for the year (2,869,746) 2,449,984 Profit (Loss) is attributed to owners of Agenix Limited (2,707,451) 2,478,187 Total comprehensive income is attributed to: owners of Agenix Limited (2,869,746) 2,449,984 Continuing operations Basic and diluted earnings per share (cents per share) (0.004) 0.054

4 Consolidated Statement of Financial Position ASSETS CURRENT ASSETS Cash and cash equivalents 1,884,584 1,736,817 Trade and other receivables 43,235 10,642 Prepayments 18,632 28,833 Other financial assets - 3,992,189 TOTAL CURRENT ASSETS 1,946,451 5,768,481 NON-CURRENT ASSETS Property, plant and equipment 25,125 33,965 Intangible assets 865,177 - TOTAL NON-CURRENT ASSETS 890,302 33,965 TOTAL ASSETS 2,836,753 5,802,446 CURRENT LIABILITIES Trade and other payables 797,472 1,472,798 Financial liabilities 52,080 1,175,485 Short-term provisions - 58,635 Current tax liabilities TOTAL CURRENT LIABILITIES 849,552 2,707,449 NON-CURRENT LIABILITIES Trade and other payables - 248,598 TOTAL NON-CURRENT LIABILITIES - 248,598 TOTAL LIABILITIES 849,552 2,956,047 NET ASSETS 1,987,201 2,846,399 EQUITY Issued capital 74,147,795 72,139,941 Share based payment reserve 4,531,942 4,529,248 Foreign currency translation reserve (155,936) 6,359 Accumulated losses (76,536,600) (73,829,149) TOTAL EQUITY 1,987,201 2,846,399

5 Notes to the Consolidated Financial Statements Note 1: Cash and Cash Equivalents Cash at bank and in hand 32, ,601 Deposits at call 1,852,357 1,304,216 Cash at bank and in hand 1,884,584 1,736,817 Cash at bank and in hand is non-interest bearing. Deposits at call bear floating interest rates between 1.4% and 6% (: 1.4% and 5%). These deposits have an average maturity of 112 days. Reconciliation of cash Cash at the end of the financial year as shown in the cash flow statement is reconciled to items in the Statement of Financial Position as follows: Cash and cash equivalents 1,884,584 1,736,817 Reconciliation of the net profit (loss) after tax to the net cash flows from operations Net profit/ (loss) after income tax (2,707,451) 2,478,187 Non cash items Depreciation of non-current assets 9,852 16,135 Share based payment expense 52,694 10,517 Revaluation increment - (4,597,065) Equity settled expenditure 80,500 - Equity settled financial liabilities 1,000,000 - Realised exchange losses on China recovery 557,875 Unrealised net foreign currency (gains) losses 118, ,619 Other 151,833 (158,884) Changes in assets and liabilities Decrease (increase) in receivables (32,593) (837) Decrease (increase) in prepayments and other current assets 10,201 (5,496) (Decrease) increase in payables (873,924) (842,712) (Decrease) increase in financial liabilities (1,123,405) 660,690 (Decrease) increase in provisions (58,635) - (Decrease) increase in taxation liabilities (531) (1,698) Net cash provided by (used in) operating activities (2,815,082) (2,291,544)

6 Notes to the Consolidated Financial Statements (continued) Note 2: Trade and Other Receivables Interest receivable - bank 24,007 - Other receivables 5,331 1,634 Australian Taxation Office 13,897 9, ,642 Note 3: Other Financial Assets CURRENT Financial assets at fair value through the Profit and Loss Opening balance 3,992,189 2,507,125 Revaluation increment - 4,597,065 Amount repaid under terms of deed (3,434,314) (2,870,175) 557,875 4,234,015 Realised foreign exchange gain (loss) (557,875) - Unrealised foreign exchange gain (loss) - (241,826) - 3,992,189 Revaluation decrement - - Net carrying amount - 3,992,189

7 Notes to the Consolidated Financial Statements (continued) Note 4: Property, Plant and Equipment Plant and equipment: At cost 51, ,038 Accumulated depreciation (26,822) (164,073) 25,125 33,965 The useful life of assets for years and was estimated as follows: Plant & Equipment over 3 to 5 years. Movements in carrying amounts Movement in the carrying amounts for each class of property, plant and equipment between the beginning and the end of the current financial year. Plant and equipment as at 1 July, net of accumulated depreciation and amortisation: 33,965 45,893 Additions 6,662 4,347 Assets disposals (net) - - Amortisation - - Depreciation (9,852) (16,135) Effect of movement in exchange rate (5,650) (140) Plant and equipment as at 30 June, net of accumulated depreciation and amortisation: 25,125 33,965 Plant and equipment which was fully depreciated and amortised in prior years and located at the previous head office was disposed of during the year for nil consideration as part of the settlement in respect of the lease.

8 Notes to the Consolidated Financial Statements (continued) Note 5: Intangible Assets AGX-1009 Contract Development costs associated with AGX-1009 Total Net carrying amount 1 July Intangible assets related to AGX-1009 acquired from IMB at cost 720, ,357 Pre-clinical trial expenditure at cost 144, ,820 Disposals at cost Less impairment losses Net carrying amount at 30 June 720, , ,177 In September, Agenix Biopharmaceutical Shanghai Co Limited entered into an exclusive agreement with the Institute of Medicinal Biotechnology (IMB) of the Chinese Academy of Medical Sciences in Beijing to purchase, develop and commercialise a patented, novel targeted prodrug analog of an existing compound (Agenix product candidate AGX-1009). IMB is a major state institution in China for the discovery and development of anti-infectious drugs. AGX-1009 is one of the drug candidates supported by the Chinese Government s State Special Funds for Important Newly- Developed Drugs. The total purchase price of AGX-1009 is RMB 17 million (equivalent to AUD 2.45 million utilising 30 June exchange rate). The purchase price is payable in instalments if performance milestones are achieved. As at 30 June instalments totalling RMB 5 million (AUD 720,357) have been paid in accordance with the agreement. In addition to the amount payable to IMB, Agenix has engaged various parties to undertake pre-clinical studies of AGX The amounts incurred to date are recorded at cost. To date, Agenix is not aware of any information regarding the pre-clinical studies that have raised concerns with the safety and efficacy of the product. As the AGX-1009 assets were acquired in an arms-length transaction and the forecast revenues from the sale of AGX-1009 demonstrate the likely use of the assets, there is no indication of impairment as at 30 June. For the purpose of impairment testing, management assesses the carrying amount by comparison to its value based upon discounting future cash flows with the assistance of independent valuers. The carrying amount of AGX-1009 was determined to be less than its recoverable amount and therefore no impairment was necessary.

9 Notes to the Consolidated Financial Statements (continued) Note 6: Trade and other payables Current Trade payables 65, ,875 Sundry payables and accrued expenses 731,543 1,210, ,472 1,472,798 Non current Sundry payables and accrued expenses - 248,598 Note 7: Financial Liabilities CURRENT Convertible notes - 1,065,890 Interest bearing loans 52, ,595 52,080 1,175,485 Convertible Notes Balance 1 July 1,065, ,795 Proceeds received on issue of notes - 1,100,000 Interest accrued on 2008/09 notes - 27,780 Interest accrued on 2009/10 notes 26,383 65,890 Interest paid during the year in relation to notes (92,273) -- Issue of securities on conversion of notes and accrued interest (1,000,000) (642,575) Balance 30 June - 1,065,890

10 Notes to the Consolidated Financial Statements (continued) Note 8: Issued Capital 747,331,576 (: 495,102,169) fully paid ordinary shares 79,516,758 77,558,904 Less: escrowed shares to SHRG vendors (5,418,963) (5,418,963) 74,097,795 72,139,941 No. No. 1 Ordinary shares. At the beginning of reporting period Issue of shares in respect of rights issue and new share offer Share placements under the Fortrend standby subscription agreement Issue of shares in lieu of employee bonus 72,139,941 71,263, ,102, ,828, ,602-32,224, ,252-6,185,255-12, ,000 - Issue of shares for services rendered Issue of performance shares to employee 80,500-3,220,000-50,000-10,000,000 - Costs of capital raisings (60,500) Issue of shares to directors in lieu of cash remuneration October 2009 Issue of shares on conversion of notes - 234,215-11,710,718 1,000, , ,000,000 47,562,740 Balance as at 30 June 74,147,795 72,139, ,331, ,102,169

11 Consolidated Statement of Cash Flows CASH FLOWS FROM OPERATING ACTIVITIES Receipts from customers - 44,687 Payments to suppliers and employees (2,805,487) (2,144,190) Payments relating to research and development (114,137) (155,055) Interest received - bank 42,703 9,186 Interest received China settlement 153,808 - Payment of Income tax (128) - Finance costs (91,841) (46,172) Net cash provided by (used in) operating activities (2,815,082) (2,291,544) CASH FLOWS FROM INVESTING ACTIVITIES Purchase of intangibles (906,876) - Proceeds arising from settlement deed in respect of China acquisition. 3,434,314 2,870,175 Purchase of property, plant and equipment (5,391) (4,347) Net cash provided by (used in) investing activities 2,522,047 2,865,828 CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issue of shares (net of costs) 798,776 - Proceeds from issue of convertible notes - 1,100,000 Repayment of borrowings (137,558) - Net cash provided by (used in) financing activities 661,217 1,100,000 Net increase in cash held 368,182 1,674,284 Cash at beginning of financial year 1,736,817 62,715 Effect of exchange rate of cash held in foreign currencies (220,415) (182) Cash at end of financial year 1,884,584 1,736,817 Dividends No dividends have been paid or proposed by the Company.

12 Consolidated Statement of Changes in Equity Issued capital Accumulated losses Share based payment reserve FX translation reserve Total equity Balance at 1 July ,263,151 (76,307,336) 4,518,731 34,562 (490,892) Total Comprehensive Income for the year: Profit (Loss) for the year - 2,478, ,478,187 Other comprehensive income: Foreign currency translation reserve differences (28,203) (28,203) Total Comprehensive Income for the year - 2,478,187 - (28,203) 2,449,984 Transactions with owners in their capacity as owners: Shares issued during the year, net of transaction costs 876, ,790 Share based payments ,517-10, ,790-10, ,307 At 30 June 72,139,941 (73,829,149) 4,529,248 6,359 2,846,399 Total Comprehensive Income for the year: Profit (Loss) for the year - (2,707,451) - - (2,707,451) Other comprehensive income: Foreign currency translation reserve differences (162,295) (162,295) Total Comprehensive Income for the year - (2,707,451) - (162,265) (2,869,746) Transactions with owners in their capacity as owners: Shares issued during the year, net of transaction costs 1,957, ,957,854 Share based payments 50,000-2,694-52,694 2,007,854-2,694-2,010,548 At 30 June 74,147,795 (76,536,600) 4,531,942 (155,936) 1,987,201 Details of Entities over which control has been gained or lost During the year the following inactive wholly owned subsidiaries were liquidated or deregistered as part of the Group s overall cost reduction programme. All the subsidiaries were dormant and held no significant assets or liabilities. Agenix Asia Pacific Pte Limited Singapore Vector Medical Solutions Inc USA Jemaka Pty Limited Australia Resource & Industry Limited Australia

13 Significant Information relating to the financial performance and financial position of Agenix Limited The Consolidated Group recorded a 2,707,451 loss from operations (: Profit 2,478,187) includes nonrecurring charges of approximately 907,000 (: 130,000) in relation to the settlement in China and a one-off write back of 157,185 finalising the lease of the surplus premises at Acacia Ridge. Cash flow continued to be impacted by the legacy of debts and lease of the previous head office, inherited from the previous Board, for which the Group had to meet its obligations. The current Board negotiated savings in excess of 900,000 of legacy issues which have now been resolved. In addition significant costs were incurred in achieving reinstatement of the company to its ASX listing and the recovery of funds in China. The recovery of funds from China was completed in December and the Company is now in a position to capitalise on the acquisition of AGX-1009 and sunk costs in the research and development on the ThromboView project. Total investment in AGX-1009 to date amounts to 1,465,628 comprising 865,177 as shown on the consolidated statement of financial position and 600,451 charged to the consolidated statement of comprehensive income. Australian Accounting Standards The financial information provided in this Appendix 4E is based upon the Annual Financial Report, which has been prepared in accordance with Australian Accounting Standards and is currently being audited by BDO Audit (QLD) Pty Limited. Commentary on Results for the year Refer above. Earnings per Share Overall Operations FY FY Basic and diluted earnings per share (cents per share) (0.004) Continuing Operations Basic and diluted earnings per share (cents per share) (0.004) Discontinued Operations Basic and diluted earnings/(loss) per share (cents per share) - - -end-